Cinqair®

Understanding Cinqair® 

Cinqair® (reslizumab) is a biologic medication used as an add-on treatment for severe eosinophilic asthma in adults. It is a monoclonal antibody that targets interleukin-5 (IL-5), a key protein involved in the growth and survival of eosinophils, which are white blood cells that contribute to airway inflammation in asthma. Cinqair® is typically prescribed for patients with severe asthma who continue to experience symptoms despite using inhalers and other standard asthma treatments. It is not for acute asthma attacks, but rather for long-term control of severe eosinophilic asthma.

How Cinqair® Works:

• Targets IL-5 to reduce eosinophil levels in the blood.
• Decreases airway inflammation, leading to improved asthma control.
• Reduces the frequency of asthma exacerbations in patients with severe eosinophilic asthma.

FDA Approval:

• 2016 – Approved for the treatment of severe eosinophilic asthma in adults.

For more information, please visit the Cinqair® patient website and speak with your healthcare provider to determine if Cinqair® is the right treatment option for you.